Beleaguered Theravance logs head-to-head trial loss for Yupelri against Boehringer's Spiriva

When Theravance called it quits on a phase 2 JAK inhibitor program last February, the South San Francisco and Dublin-based biopharma company put the majority of its chips on a head-to-head trial pitting its Viatris-partnered bronchodilator Yupelri against Boehringer Ingelheim’s Spiriva in chronic obstructive pulmonary disease (COPD).